Naitive Technologies Ltd., a population health company dedicated to developing innovative solutions in musculoskeletal care, has announced a strategic agreement with Parvizi Surgical Innovation (PSI) to advance the development and clinical deployment of OsteoSight.
OsteoSight is designed for the early identification of low bone mineral density. Naitive says this partnership aligns it with some of the leading orthopaedic surgeons in the world, giving them unique insights into the needs and demands of front-line healthcare providers.
OsteoSight uses AI to opportunistically scan through millions of routine X-rays for evidence of low bone mineral density, an early warning sign of osteoporosis, and was granted FDA Breakthrough Device Designation last year.
With PSI’s experience in research, product development, and musculoskeletal care, Naitive says this collaboration aims to expedite the validation and implementation of OsteoSight within clinical settings, making it more accessible to millions of people with undiagnosed osteoporosis.
Read more: University of Iowa Health Care and Naitive announce project to improve osteoporosis care
“Orthopaedic surgeons are uniquely positioned to identify and address osteoporosis at an early stage, meaning more effective and accessible interventions for patients. We’re excited to collaborate with Naitive, whose commitment to integrating clinical user feedback into their technology development is evident, and by ensuring OsteoSight aligns with clinical workflows, they’re setting the standard in user-centred innovation,” said Dr. Javad Parvizi, Founder & CEO of PSI.
“Our members include some of the world’s foremost orthopaedic surgeons, and their expertise will be invaluable in ensuring OsteoSight™ delivers great clinical value and fits into the workflows of busy orthopaedic practices.”
Dr. Wael Barsoum, member of Parvizi Surgical Innovation and President of HOPCo said: “Naitive has consistently demonstrated a commitment to advancing healthcare for both patients and providers through robust technology and sound business practices.
“Having collaborated with Naitive on several research initiatives in my role at HOPCo, I’ve seen firsthand the potential of OsteoSight and the value it can bring to musculoskeletal care. At PSI, we see a tremendous opportunity to enhance this technology and to improve patient outcomes.”
“We are delighted to partner with Parvizi Surgical Innovation, whose knowledge and network in orthopaedic surgery will be invaluable as we move OsteoSight closer to clinical adoption,” said Dr. Will Briggs, CEO of Naitive. “With PSI’s support, we’re ensuring our technology meets the rigorous standards of clinical care but also seamlessly integrates into real-world orthopedic workflows.
“Their leadership in musculoskeletal care, combined with our breakthrough technology, will help us make significant advancements in the early diagnosis and treatment of osteoporosis.”
